About Wessex AHSN
Centre for Implementation Science
Frequently asked questions
What is the concern about Atrial Fibrillation (AF)?
By Sharron Gordon, Pharmacist Consultant Anticoagulation, Faculty Fellow of The Royal Pharmaceutical Society and Wessex AHSN AF leadAtrial Fibrilla...
EY Tuesday: What’s the right path to accelerate your growth journey?, 28th March 2017
Newsletters, annual reports...
This project will sequence 100,000 whole genomes from about 70,000 NHS patients with either certain types of cancer or patients with rare disease plus their families.
With consent patients’ genomes will be sequenced and linked to details about an individual’s medical condition. Doing this may help medical teams provide better diagnosis or treatment in some cases. In other cases, not enough may yet be known about a particular cancer or rare disease to interpret an individual’s data.
By adding key information from medical records, and securely collating data, scientists can compare tens, hundreds or even thousands of people with the same rare condition. Allowing approved scientists to have monitored access to this data will improve our understanding of ill health and how to treat it.
Aims of the project:
“This project has the potential to transform the future of healthcare and we are delighted many patients from across the south can be involved and will benefit from it. It will improve the prediction and prevention of disease, enable new and more precise diagnostic tests and allow personalisation of drugs and other treatments to specific genetic variants.”
Professor Karen Temple, clinical geneticist, UHS; co-lead, Wessex NHS GMC
UHS Clinical Research update - Issue 5, Autumn 2015
Wessex GMC bulletin - August 2016